| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Ovid Therapeutics Inc.$2.32
+0.11 (+4.89%)
Market Cap
461.00 M
EPS
-0.24
P/E Ratio
-
Value Trade
5.16 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
11.18 M
Operating CF
-13.90 M
Total Assets
225.63 M
Total Liabilities
27.36 M
Equity
198.27 M
D/E Ratio
12,345
-11.94 %
Week
-13.94 %
1 Month
63.58 %
3 Month
99.19 %
6 Month
-36.99 %
5 Year
-82.36 %
All Time
Cash Data
Cash Position
155.52 M
Monthly Burn
4.63 M
Runway
32.4 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
2.42 M
52 Week Range
0.27 - 3.11
% held by Insiders
9.52 %
% held by Institutions
58.84 %
Enterprise Value
318.55 M
Total Shares
130.24 M
Short %
10.89 %
Float Shares
97.68 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
OV329 | treatment-resistant seizures,pain | Phase 1 | 2025-08-14 | |||
OV329 | treatment-resistant seizures,pain | Phase 1 | 2025-08-14 | |||
OV329 | treatment-resistant seizures,pain | Phase 1 | 2025-08-14 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OVID
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Ovid Therapeutics Inc. (OVID) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
OVID
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OVID
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OVID
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OVID Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
OVID Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
OVIDOvid Therapeutics to Participate in Upcoming Investor Conferences
Ovid Therapeutics Inc., a biopharmaceutical company focused on brain disorders, has announced its participation in two upcoming investor conferences. The Oppenheimer CNS & Neuro-Muscular Summit will take place on June 10, followed by the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15. These events provide the company an opportunity to showcase their development of innovative therapies for neurological conditions. A live webcast of the presentations will be accessible on the company’s website, with an archived version available for 30 days afterward.
Read more →OVIDOvid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
Ovid Therapeutics has appointed Dr. Anna Greka to its Board of Directors, effective June 15, 2026. Dr. Greka, a renowned physician-scientist, brings over 25 years of experience in advancing biological discoveries into clinical-stage therapies. She will chair the newly formed Science and Technology Committee and contribute to the Compensation Committee.
Read more →OVIDOvid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
Ovid Therapeutics reported positive business updates and financial results for Q1 2026, highlighting the initiation of a Phase 1 study for OV4071 and favorable results for OV329. The company plans to expand OV329's development into pediatric indications and has strengthened its financial position with significant capital raised. However, it also reported a net loss and increased expenses compared to the previous year.
Read more →OVIDOvid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
Ovid Therapeutics will host a KCC2 Deep Dive R&D event on April 14, 2026, in New York. The event will showcase their first-in-class KCC2 portfolio, including direct activators for various neurological disorders. Leading experts will discuss pharmacodynamic data and the clinical development strategy. A live webcast will be available for participants.
Read more →OVIDOvid Therapeutics Announces Pricing of $60 Million Private Placement
Ovid Therapeutics announced a $60 million private placement financing expected to close on March 19, 2026. The funds will be used primarily to advance the development of OV329, a next-generation GABA-aminotransferase inhibitor, into additional indications such as tuberous sclerosis complex and infantile spasms. The transaction is led by Point72 and includes various other investors. The company will sell a total of 19,154,321 shares at $2.01 per share, plus warrants at a lower price. This financing is critical for addressing significant unmet medical needs in the field of brain disorders.
Read more →OVIDOvid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results The 7 mg dose of OV329 demonstrated favorable safety and
Ovid Therapeutics has announced key developments, including new data for its GABA-AT inhibitor OV329, which shows favorable safety and tolerability, prompting plans for a Phase 2 trial in refractory epilepsies. The company is also expanding OV329's indication to include tuberous sclerosis complex seizures and infantile spasms, backed by a $60 million private placement. Additionally, OV4071, a novel oral KCC2 activator, has received clearance for its Phase 1 trial following approval from the Australian Therapeutic Goods Administration.
Read more →OVIDOvid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) OV350 showed a good safety profile, supporting the advancement of the Com
Ovid Therapeutics has reported promising Phase 1 results for OV350, the first direct activator of the KCC2 transporter dosed in humans. The study successfully demonstrated safety, tolerability, and pharmacokinetics, prompting the company to advance its oral KCC2 direct activator programs. Ovid is now focusing on OV4071, expecting to initiate clinical studies in 2026. Despite the positive news, Ovid has decided not to continue developing OV350 in further clinical settings.
Read more →OVIDOvid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
Ovid Therapeutics has appointed Dr. Petra Kaufmann as Chief Medical Officer. Dr. Kaufmann, with a strong background in CNS therapeutics and regulatory experience, will guide Ovid's clinical and medical strategies. Her expertise is expected to enhance the development of Ovid's pipeline, including the next-generation GABA-AT inhibitor, OV329.
Read more →OVIDOvid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Ovid Therapeutics announced a leadership succession plan with Meg Alexander set to become CEO on January 1, 2026, while Dr. Jeremy M. Levin transitions to Executive Chairman. The company reported strong financial results for Q3 2025 and highlighted advancements in its clinical pipeline, particularly with OV329 and KCC2 programs. Ovid is positioned for significant developments in the coming months.
Read more →OVIDOvid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
Ovid Therapeutics has announced a private placement financing expected to yield up to $175 million in gross proceeds. The financing includes participation from both new and existing investors and is set to close around October 6, 2025. Proceeds will be utilized for research and development, corporate expenses, and working capital needs.
Read more →OVIDOvid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
Ovid Therapeutics announced positive topline results from a Phase 1 study of OV329, a next-generation GABA-aminotransferase inhibitor aimed at treating drug-resistant epilepsies. The trial demonstrated OV329's safety, tolerability, and pharmacodynamic activity, with a favorable safety profile. The results indicate potential for further development in patient studies, reinforcing OV329's therapeutic promise.
Read more →OVIDOvid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
Ovid Therapeutics has reported positive advancements in its clinical pipeline, including the upcoming Phase 1 readout for OV329, a GABA-AT inhibitor aimed at treating drug-resistant seizures. The company also plans to initiate a Phase 1/1b study for OV4071 in early 2026. Additionally, Ovid has strengthened its financial position through the sale of ganaxolone royalty rights, allowing for continued focus on its innovative small molecule therapies.
Read more →OVIDOvid Therapeutics to Participate in the BTIG Virtual Biotech Conference
Ovid Therapeutics Inc. will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. The company is dedicated to developing small molecule medicines for brain conditions with significant unmet needs. Their pipeline includes several promising candidates aimed at treating neurological and neuropsychiatric disorders.
Read more →OVIDOvid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Ovid Therapeutics has entered a definitive agreement with Immedica Pharma AB for the sale of future royalties related to ganaxolone outside of China. Immedica will pay $7 million to acquire these rights, providing Ovid with non-dilutive capital to support ongoing operations. The transaction does not impact Ovid's current pipeline, as the company is not pursuing further development of ganaxolone.
Read more →OVIDOvid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Ovid Therapeutics will host an investor and media event on June 12, 2025, focusing on the application of biomarkers in epilepsy and their role in the OV329 clinical development program. The event will feature Dr. Alexander Rotenberg and discuss the use of biomarkers in drug development. OV329 aims to provide a novel treatment option for patients with treatment-resistant seizures.
Read more →OVIDOvid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid
Ovid Therapeutics announced business updates and financial results for Q1 2025, highlighting progress in its clinical pipeline, particularly with OV329, a potential treatment for drug-resistant seizures. The company plans to release key safety and biomarker data for OV329 in Q3 2025. Additionally, initial results from the Phase 1 study of OV350 are expected by year-end 2025. Despite a net loss reported for the quarter, Ovid maintains a stable cash position, allowing operations to continue into the second half of 2026.
Read more →OVIDOvid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Ovid Therapeutics announced that Meg Alexander, its President and COO, will present at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025. The event will showcase the company's efforts in developing therapies for neurological disorders. A live webcast will be available, with an archived replay accessible for 30 days post-event.
Read more →OVIDOvid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors two industry veterans joined
Ovid Therapeutics has announced key business updates and financial results for 2024, detailing the advancement of their clinical pipeline, including OV329 and a KCC2 direct activator. The company has appointed prominent leaders to its management team and boasts a solid cash position expected to support operations into 2026. Expecting critical data and trial milestones in the coming years, Ovid aims to capitalize on the unmet needs in neurotherapeutics. The company also emphasizes fiscal discipline while navigating potential challenges in capital acquisition for ongoing projects.
Read more →OVIDOvid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
Ovid Therapeutics announced the appointment of Dr. Stelios Papadopoulos to its Board of Directors, highlighting his extensive experience in the biotechnology sector. Dr. Papadopoulos, known for his strategic influence in biotechnology, is expected to bolster Ovid's leadership during a critical time for the company. The firm is working on innovative treatments for brain conditions, with programs like the KCC2 activators and OV329 for epilepsy. His role aims to drive growth and advance Ovid's development pipeline focused on addressing neurological and psychiatric disorders.
Read more →OVIDOvid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Ovid Therapeutics Inc. will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025. Meg Alexander, the President and Chief Operating Officer, will be leading the presentation. Ovid focuses on medicine development for brain conditions with unmet needs, showcasing its innovations in targeted small molecule candidates.
Read more →OVIDOvid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Ovid Therapeutics Inc. announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, scheduled for February 12, 2025. The company will present virtually, providing insights into its pipeline of therapies targeting neurological and neuropsychiatric disorders. Ovid aims to address significant unmet medical needs in brain conditions through its novel drug candidates, which include OV329, OV350, and OV888/GV101. Interested viewers can access the live presentation via the company's website.
Read more →OVIDOvid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
Ovid Therapeutics has announced that it will present four posters at the American Epilepsy Society 2024 Annual Meeting, showcasing its pipeline programs OV329 and OV350, which target neuronal hyperexcitability. Preclinical studies indicate that OV329, a GABA aminotransferase inhibitor, has a favorable safety profile by not accumulating in the retina and effectively suppressing seizures. Additionally, OV350, a KCC2 direct activator, is expected to exhibit neuroprotective benefits. The company aims to continue advancing these promising therapies, addressing critical needs in epilepsy treatment.
Read more →OVIDOvid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
Ovid Therapeutics provided updates on its business performance and financial results for Q3 2024, highlighting progress in its drug development pipeline. The Phase 1 study of OV329 is advancing positively, prompting discussions with regulators for expanding dosing opportunities. Additionally, the company plans to submit a regulatory application for a Phase 1 trial of OV350 by year-end 2024. However, Ovid is pausing the Phase 2 study of OV888/GV101 to evaluate insights from competitor trials in cerebral cavernous malformations.
Read more →OVIDOvid Therapeutics to Host Investor Event
Ovid Therapeutics Inc. announced an investor event scheduled for November 13, 2024, to discuss its KCC2 activator portfolio. The event will be held at the company's headquarters in New York and will include presentations from leading experts in the field of neurology. The aim is to highlight the therapeutic potential of Ovid's ongoing programs including OV350, which is designed to address rare neurological conditions. Ovid's press release emphasizes the innovative nature of its drug pipeline while noting the inherent risks of drug development.
Read more →OVIDOvid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
Ovid Therapeutics has presented promising pre-clinical study results at the Epilepsy Pipeline Conference, demonstrating their product OV329 does not accumulate in the retina or other tissues in comparison to vigabatrin. The study indicates that OV329's short half-life and rapid tissue elimination may allow for a safer treatment option for seizures associated with rare epilepsies. A Phase 1 trial involving healthy volunteers is set to complete in late 2024, which will further evaluate the drug's safety and potential clinical effects.
Read more →OVIDOvid Therapeutics to Present at Upcoming September Investor Conferences
Ovid Therapeutics Inc. has announced its participation in two investor conferences in September, enhancing its engagement with investors. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10th and participate in a fireside chat at the Cantor Global Healthcare Conference on September 17th. Webcasts for both events will be accessible on Ovid's website, supporting transparency and investor relations. Ovid is dedicated to developing targeted therapies for rare epilepsies and other neurological conditions.
Read more →OVIDOvid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
Ovid Therapeutics has announced significant business updates and financial results for Q2 2024. The company appointed Dr. Amanda Banks as Chief Development Officer to strengthen its clinical strategy, while also reducing its workforce by 43% to streamline operations. Despite these cuts, Ovid maintains a solid cash position of $77.0 million expected to support operations through late H1 2026, aiming for five clinical and regulatory milestones in that timeframe. The company reported positive developments for its OV888/GV101 program, although it has suspended the OV329 IV program as part of its portfolio prioritization efforts.
Read more →OVIDOvid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
Ovid Therapeutics has appointed Dr. Amanda Banks as its Chief Development Officer to lead clinical development and corporate strategy. Dr. Banks, who has extensive experience in neurology and business development, is set to guide the company during a crucial phase as it explores therapeutic opportunities linked to its innovative programs. She emphasizes the importance of focusing on the pipeline to address significant unmet medical needs in neurological disorders. Her leadership aims to enhance Ovid's efforts in developing novel treatments for rare brain conditions.
Read more →OVIDOvid Therapeutics to Present at Upcoming August Investor Conferences
Ovid Therapeutics Inc. will be presenting at two upcoming investor conferences in August 2024, including a fireside chat at the BTIG Virtual Biotechnology Conference and a panel discussion at the Wedbush PacGrow Healthcare Conference. These presentations will focus on the company's advancements in treating certain epilepsies and brain conditions through its novel therapies. Live webcasts will be available, along with archived replays on the company's website. Ovid continues to develop several targeted small molecule candidates aimed at addressing neurological disorders.
Read more →OVIDOvid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
Ovid Therapeutics has expanded its Scientific Advisory Board (SAB) by adding leading neurologists, neuroscientists, and epileptologists. The new board members will contribute their expertise to explore the potential applications of Ovid's compounds for various neurological disorders. Ovid aims to advance its research and clinical development strategies focused on ROCK2 inhibitors and KCC2 direct activators. The SAB is expected to play a crucial role in guiding the translation of these programs into actionable clinical applications.
Read more →OVIDOvid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888 GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations The Phase 1 study for OV
Ovid Therapeutics and Graviton Bioscience have announced positive topline results from the Phase 1 clinical trial of OV888 GV101 capsule. The trial met its primary objectives, showing a favorable safety and tolerability profile with no serious adverse events. The treatment demonstrated biological activity, supporting its potential as a first-in-class oral therapy for Cerebral Cavernous Malformations, a condition with no FDA-approved pharmacologic treatments. A Phase 2 proof-of-concept study is anticipated to start in late 2024.
Read more →OVIDOvid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat • Takeda's Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizu
Ovid Therapeutics reported on the topline results of Takeda's Phase 3 studies for soticlestat, indicating that while the primary endpoints for both the SKYLINE and SKYWAY studies were not met, there were significant results in key secondary endpoints. The studies aimed to assess the efficacy of soticlestat in treating Dravet syndrome and Lennox-Gastaut syndrome. Despite these missed targets, Ovid has established a strong pipeline of clinical programs and expects to continue advancing its R&D efforts with several milestones expected in the near future. Ovid CEO Jeremy Levin remarked on the disappointment of the results but emphasized the unique action mechanism of soticlestat and the company's commitment to its independent projects.
Read more →OVIDOvid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome topline data
Ovid Therapeutics provided a business update alongside its financial results for the first quarter of 2024. Key highlights include the completion of a Phase 1 trial for OV888 and the anticipation of topline data for soticlestat from Takeda's Phase 3 trials. The company reported a financial position with $90.3 million in cash, expected to sustain operations until H1 2026. Overall, Ovid aims to address significant unmet needs in the treatment of epilepsies and related brain conditions through its developing pipeline.
Read more →OVIDOvid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Ovid Therapeutics Inc. announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference scheduled for May 20, 2024. The company, focused on developing treatments for rare epilepsies and brain conditions, will present management insights through a live webcast. Ovid’s pipeline includes several novel candidates targeting seizure-related disorders, reflecting its commitment to improving patient outcomes. However, forward-looking statements emphasize risks associated with clinical development and financial objectives.
Read more →OVIDOvid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Ovid Therapeutics Inc. announced that its management will participate in the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024. The presentation will be accessible via a live webcast, with an archived version available afterward. Ovid is focused on developing targeted treatments for rare epilepsies and brain conditions, accompanied by a pipeline that includes several promising candidates currently under investigation. Despite the optimistic outlook for its therapies, the company faces inherent risks associated with clinical development and regulatory approvals.
Read more →OVIDOvid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrom
Ovid Therapeutics provided updates on its business and financial results for the fourth quarter and full year of 2023. The company is progressing with two pivotal Phase 3 trials for soticlestat, aimed at treating Lennox-Gastaut syndrome and Dravet syndrome, with data expected by September 2024. Additionally, Ovid plans to advance several clinical programs, including a Phase 2 study of OV888 (GV101) and progress in the OV329 program. However, the company reported a decrease in revenue compared to the previous year.
Read more →OVIDOvid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
Ovid Therapeutics Inc. announced its participation in a panel discussion titled 'Orphan Epilepsies' at the TD Cowen 44th Annual Health Care Conference on March 6, 2024. The event will focus on advancements in treatments for epilepsy and associated brain disorders. Ovid is developing several targeted therapies including OV329 and OV888, aiming to address treatment-resistant conditions. The company's pipeline and ongoing research highlight its commitment to improving patient outcomes in neurology.
Read more →OVIDOvid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Ovid Therapeutics Inc. announced that it will participate in a virtual presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The presentation will focus on their ongoing development of treatments for epilepsy and related brain disorders. This participation allows Ovid to showcase its innovative pipeline, including potential therapies like OV329, OV888, and OV350, aimed at modulating neuronal hyperexcitability. A live webcast of the presentation will be available on the company’s website.
Read more →OVIDOvid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
Ovid Therapeutics Inc. is set to present five posters at the 2023 American Epilepsy Society Annual Meeting, focusing on OV329 and OV350, which are aimed at treating epilepsy and treatment-resistant seizures. The new preclinical data on OV329 indicates it may outperform existing GABA-aminotransferase inhibitors, while OV350 demonstrates potential for monotherapy and as a benzodiazepine potentiator. These developments underline Ovid's commitment to addressing significant unmet needs in seizure treatment.
Read more →OVIDOvid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed
Ovid Therapeutics reported its third quarter 2023 financial results, highlighting a $30 million payment from Ligand that monetized a 13% portion of future royalties on its lead product soticlestat. The company revealed that it expects this infusion of capital to extend its cash runway into 2026 while retaining a substantial interest in soticlestat's future payouts. Clinical trials for soticlestat are on track for regulatory filing in fiscal year 2024, and Ovid anticipates reaching five clinical and regulatory milestones in the next 15 months, alongside advancements in its pipeline programs.
Read more →OVIDOvid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026 • Ligand will receive 13% of all so
Ovid Therapeutics and Ligand Pharmaceuticals have entered into a $30 million agreement in which Ligand will acquire a 13% interest in soticlestat royalties and milestones. This transaction provides Ovid with a non-dilutive cash infusion, extending its financial runway into 2026. Notably, Ovid retains 87% of the interest in soticlestat, a potential treatment for Lennox-Gastaut syndrome and Dravet syndrome, signifying strong investment confidence in the drug's market potential. The deal highlights both companies' commitment to addressing unmet medical needs in the epilepsy treatment landscape.
Read more →OVIDOvid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
Ovid Therapeutics Inc. will present at the Jefferies Biotech CNS/Neuro Summit on October 12, 2023. The presentation will highlight the company's commitment to developing treatments for epilepsies and seizure-related disorders. Ovid has a focused pipeline, including therapies such as OV888 and OV329 aimed at treating various neurological conditions. The company's significant financial interest in the regulatory development of soticlestat, currently in Phase 3 trials, is also noteworthy.
Read more →OVIDOVID R&D DAY OCTOBER 2, 2023 Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman Forward looking statement This presentation contains “forward-looking statements” within the meaning of the Pri
Ovid's R&D Day highlighted the company's innovative pipeline aimed at treating epilepsy and CNS disorders. CEO Dr. Jeremy Levin emphasized the potential benefits of their product candidates, including OV329 and OV888, which are designed to target rare forms of epilepsy and enhance treatment options. The company expects significant clinical milestones in the upcoming 12-15 months and positive financial backing from Takeda if soticlestat is commercialized. However, Ovid continues to navigate risks related to clinical development and achieving financial goals.
Read more →OVIDOvid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
Ovid Therapeutics has announced it will host an Investor R&D Day on October 2, 2023, at its headquarters in New York. The event aims to update stakeholders on the company's scientific strategy and clinical development plans. Experts in epilepsy and neurological disorders will present new data on Ovid's pipeline, emphasizing its unique mechanisms of action. The event will also be available via a live webcast for wider accessibility.
Read more →OVIDOvid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
Ovid Therapeutics Inc. has announced its participation in the 2023 Cantor Fitzgerald Global Healthcare Conference, scheduled for September 26, 2023. The company will present its pipeline of targeted treatments for epilepsies and seizure-related disorders. Their notable programs include OV329, GV101, and OV350, each addressing specific neurological conditions. However, the announcement includes several forward-looking statements that convey inherent uncertainties and potential challenges in achieving their developmental and financial goals.
Read more →OVIDOvid Therapeutics to Participate in Upcoming September Investor Conferences
Ovid Therapeutics Inc. has announced its participation in two upcoming investor conferences, specifically the Citi’s 18th Annual BioPharma Conference and the H.C. Wainwright 25th Annual Global Investment Conference. The events are set to take place on September 7 and September 12, 2023, respectively. This engagement highlights Ovid's commitment to sharing its research and developments with the investment community, particularly in the field of epilepsy and neurological disorders.
Read more →OVIDOvid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inh
Ovid Therapeutics reported their second quarter 2023 financial results and announced significant corporate updates including the completion of the single ascending dose portion of a Phase 1 trial for OV329. The company has entered into a collaboration with Graviton Bioscience to develop ROCK2 inhibitors, increasing their pipeline of therapeutic options. Financial results indicate a modest revenue and highlight cost-cutting measures as part of enhancing efficiency. Anticipated regulatory filings for soticlestat could lead to potential multi-million dollar payments.
Read more →OVIDOvid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
Ovid Therapeutics Inc. announced its participation in the BTIG Virtual Biotechnology Conference on August 7, 2023, where management will conduct a fireside chat. The company focuses on developing innovative medicines for patients with epilepsies and seizure-related disorders. Its pipeline includes small molecule candidates aimed at treating various neurological conditions, indicating a commitment to addressing unmet medical needs. Ovid also maintains a significant interest in the Phase 3 trials of soticlestat, a medication being developed by Takeda for specific epilepsy syndromes.
Read more →OVIDOvid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
Ovid Therapeutics has announced the appointment of Dr. Zhong Zhong as Chief Scientific Officer and Dr. Manoj Malhotra as Chief Medical Officer following the retirement of Dr. Claude Nicaise. Additionally, Meg Alexander has been promoted to Chief Strategy Officer. These changes aim to improve operational efficiency and support the company's ongoing commitment to developing innovative therapies for rare epilepsies and seizure-related disorders. Ovid is also implementing cost reductions to enhance infrastructure alongside its strategic initiatives.
Read more →OVIDOvid Therapeutics Added to Russell 3000 Index
Ovid Therapeutics Inc. has been added to the Russell 3000 Index, effective June 26, 2023. This inclusion comes as part of the annual reconstitution of the Russell indexes, aimed at improving visibility and investment opportunities for the company. Ovid's Chairman and CEO, Jeremy Levin, indicated that this increased exposure could help attract investors interested in the company’s potential data and regulatory milestones. Ovid is focused on developing innovative medicines for epilepsy and other brain disorders.
Read more →OVIDOvid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseases Long-term data su
Ovid Therapeutics reported its financial results for Q1 2023 and announced several corporate updates, including a new collaboration with Graviton Bioscience aimed at developing ROCK2 inhibitors for rare neurological diseases. The company highlights ongoing progress with its pipeline, especially in the development of soticlestat, which has shown positive long-term safety and efficacy data. Ovid anticipates its cash runway will fund operations into 2025, allowing continued investment in clinical programs and strategic initiatives. Additionally, the company plans to conclude its genetic medicine collaboration with Columbia University in favor of focusing on small molecule programs.
Read more →OVIDOvid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors • Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological dis
Ovid Therapeutics has announced a collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors aimed at treating rare neurological disorders. The partnership combines Ovid's expertise in central nervous system development with Graviton's knowledge in RhoA/ROCK2 signaling. Ovid will invest $10 million in the collaboration and will primarily focus on developing the candidate GV101, which is currently in Phase 1 trials, as well as other ROCK2 compounds. This initiative aims to offer new treatment options for conditions such as cerebral cavernous malformations and seizures, representing a significant advancement in the field.
Read more →OVIDLong-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting • Interim 2-year findings show soticlestat appeared generally sa
Takeda Pharmaceuticals presented the interim findings from the ENDYMION 1 study at the American Academy of Neurology meeting, highlighting the long-term safety and efficacy of soticlestat for treating patients with Dravet and Lennox-Gastaut syndromes. The study reported sustained reduction in seizure frequencies for both conditions over a two-year period, with most patients tolerating the drug well. Ovid Therapeutics maintains significant financial interests in soticlestat's development, as it is anticipated to play a crucial role in addressing these refractory epilepsies.
Read more →OVIDOvid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
Ovid Therapeutics Inc. announced its participation in the 22nd Annual Needham Virtual Healthcare Conference scheduled for April 17, 2023. The event will showcase Ovid's initiatives in developing innovative treatments for epilepsy and seizure-related disorders. The company is working on multiple therapeutic candidates including OV329 and OV350. However, like many biopharmaceutical firms, Ovid faces risks tied to the uncertainties of clinical trial results and regulatory approvals.
Read more →OVIDOvid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results OV329 Phase 1 trial is progressing on track An IV formulation candidate suitable for future clinical trials has been achieved
Ovid Therapeutics recently reported its business update and financial results for 2022, highlighting positive progress in its OV329 Phase 1 trial and the successful formulation of OV350 for future clinical trials. The company's financial strategy includes cost-cutting measures and a cash runway expected to last into mid-2025. However, the financial results showed a notable decrease in revenue and a significant net loss compared to the previous year, largely influenced by one-time payments received in 2021. Ovid aims to improve its pipeline of anti-seizure medicines while mitigating risks with disciplined business development activities.
Read more →OVIDOvid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
Ovid Therapeutics Inc. has announced its participation in the upcoming 2nd Annual Needham Virtual Neuroscience Forum on March 15, 2023. The presentation will focus on the company’s efforts to develop treatments for epilepsy and brain disorders, including the investigational drugs OV329 and OV350. A live webcast of the event will be available on Ovid's investor website. The company also holds important interests in the global development of soticlestat, which is currently in late-stage trials.
Read more →OVIDOvid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
Ovid Therapeutics Inc. announced its participation in the Cowen 43rd Annual Healthcare Conference in Boston, where it will present a panel titled 'Orphan Epilepsies.' This event highlights Ovid's ongoing commitment to addressing the needs of individuals affected by epilepsies and brain disorders. The presentation will include insights into their research and development pipeline, which consists of novel therapies for treatment-resistant seizures and other epilepsy-related conditions.
Read more →OVIDOvid Therapeutics Expands Epilepsy Development Expertise with New Appointments
Ovid Therapeutics Inc. is expanding its medical and development team by appointing Dr. Manoj Malhotra as Chief Medical Officer and Dr. Toshiya Nishi as Head of Epilepsy Research. Dr. Malhotra brings significant experience in epilepsy clinical trials, having previously held senior roles at major pharmaceutical companies. Dr. Nishi collaborates with Ovid as a co-inventor of soticlestat and will concentrate on developing innovative epilepsy treatments. Both appointments aim to strengthen Ovid's leadership in developing therapies for seizures and brain disorders.
Read more →OVIDOvid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
Ovid Therapeutics has started dosing healthy volunteers with OV329 in a Phase 1 trial to evaluate its safety and effectiveness for epilepsy treatment. OV329 is a GABA-aminotransferase inhibitor designed to reduce seizures in patients resistant to current therapies. The trial, conducted at Duke University, will measure various parameters including pharmacokinetics and target engagement. Results are expected in the first half of 2024, and the company aims to address significant unmet needs in the epilepsy community.
Read more →OVIDOvid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)
Preclinical data demonstrate potential efficacy and safety of OV329 at low, chronic dosing, suggesting an improved profile compared to other GABA-aminotransferase inhibitors Data from the NIH/NINDs Epilepsy Therapy Screening Program demonstrate that OV329 confers protection from
Read more →OVIDOvid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights Ovid intends to initiate a Phase 1 study in healthy volunteers in Q4 2022, following the FDA clearance of an Investigational New Dru
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights Ovid intends to initiate a Phase 1 study in healthy volunteers in Q4 2022, following the FDA clearance of an Investigational New Drug (IND) application for OV329, its GABA-aminotransferase in
Read more →OVIDOvid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will prese
Read more →OVIDOvid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will prese
Read more →OVIDOvid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Ph
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the second half of 2022 Presented preclinic
Read more →OVIDOvid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference
OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizures Data demonstrate OV329 has the potential for an improved ocular safety profile and therapeutic index compared to other GABA-aminotransferas
Read more →OVIDOvid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights • Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase inhibitor,
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights -Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase inhibitor, and initiating Phase 1 trials in the fourth quarter of 2022 -Data
Read more →OVIDOvid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the
Read more →OVIDOvid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results • Ovid executing on its strategy to build a leading epilepsy pipeline • OV329 expected to enter the clinic in 2
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results -Ovid executing on its strategy to build a leading epilepsy pipeline -OV329 expected to enter the clinic in 2022 -Organization reshaped to reduce personnel by 20% and increase operat
Read more →OVIDOvid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people affected by epilepsies and rare neurological disorders, today announced that management will partic
Read more →OVIDOvid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid's franchise of potential first-in-class anti-epi
Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators NEW YORK, January 3, 2022 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today ann
Read more →OVIDOvid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results Ovid is implementing its business development program which intends to secure a series of opportunities that comple
Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results NEW YORK, November 10, 2021 Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rar
Read more →OVIDOvid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Kevin Fitzgerald, Ph.D., to i
Read more →OVIDOvid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today announced that management will present in a virtual format at the
Read more →OVIDDisclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect
Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect," "plan," "anticipate" and similar expressions (as well as
Read more →OVIDOvid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights Company ends Q2 '21 with cash and cash equivalents of $212.2 million Recent appointments to Company leadership strongly position Ov
Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights NEW YORK, August 16, 2021 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseas
Read more →OVIDOvid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities
Dr. Michael Poole to Join the Board of Directors Dr. Claude Nicaise Appointed Head of R&D and Jason Tardio Appointed Chief Operating Officer Dr. Amit Rakhit to Join the Scientific and Clinical Advisory Board NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (N
Read more →OVIDOvid Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present in a virtual format at
Read more →OVIDDisclaimers and Forward-Looking Statements 2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 199
These statements are based on the Company's current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statem
Read more →OVIDOvid Therapeutics Appoints Jeff Rona as Chief Business and Financial Officer
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that current Chief Business Officer Jeffrey Rona ha
Read more →OVIDOvid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A. Sullenger to its Scientific Advisory Board
New appointments strengthen neuroscience-focused Scientific Advisory Board NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological di
Read more →OVIDOvid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update Closed royalty, license and termination agreement with Takeda for soticlestat; Ovid Therapeutics received an upfront payment of
Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update NEW YORK, May 13, 2021 - Ovid Therapeutics Inc. (NASDAQ: OVID) ("Ovid"), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurol
Read more →OVIDOvid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will participate in a virtual firesi
Read more →OVIDOvid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory Board
NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Professor Robert S. Langer,
Read more →OVIDOVID Provides Update on OV101 Program and the Prioritization of its Resources Completed Soticlestat Agreement with Takeda Provides Significant Resources to Advance and Enrich OVID's Pipeline, Including OV882 for Angelman
OVID Provides Update on OV101 Program and the Prioritization of its Resources Completed Soticlestat Agreement with Takeda Provides Significant Resources to Advance and Enrich OVID's Pipeline, Including OV882 for Angelman Syndrome Company Reiterates Anticipated Quarterly Operati
Read more →OVIDOvid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat New York
Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat New York, March 30, 2021 -Ovid Therapeutics Inc. (NASDAQ: OVID) ("Ovid"), a biopharmaceutical company committed to developing medicines that transform the liv
Read more →OVIDOvid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021 Announced signing of transaction transferring Ovid's 50% of global rights to develop and commercialize sot
Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021 NEW YORK, March 15, 2021 - Ovid Therapeutics Inc. (NASDAQ: OVID) ("Ovid"), a biopharmaceutical company committed to developing medicines that transform the lives of
Read more →OVIDOvid Therapeutics Announces Addition to the Nasdaq Biotechnology Index
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Nasdaq Biotechnology
Read more →OVIDOvid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint • OV101 program in Angelman syndrome to pause pending full analysis of NEPTU
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint NEW YORK, December 1, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transf
Read more →OVIDOvid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress
NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that abstracts from the TAK-935/OV935 (soticlestat)
Read more →OVIDOvid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update • On track to report topline results from pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome in Q4 2020 •
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update NEW YORK, November 12, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologi
Read more →OVIDOvid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program
NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced it will host an educational webinar on Thursday, Oc
Read more →OVIDOvid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual Congress
Four abstracts from the OV101 (gaboxadol) clinical development program in Angelman Syndrome and Fragile X Syndrome to be presented NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines tha
Read more →OVIDOvid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies • Results from signal-finding, pilot Phase 2 open-label ARCADE study and
Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies NEW YORK, September 30, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that
Read more →OVIDOvid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present at the 2020 Cantor Fi
Read more →OVIDPhase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome Primary endpoint achieved, demonstrating a s
Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome New York and Osaka, Japan, August 25, 2020 -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") a
Read more →OVIDOvid Therapeutics Announces Pricing of $50 Million Offering of Common Stock
Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock NEW YORK, August 25, 2020 (GLOBE NEWSWIRE) Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurologica
Read more →OVIDOvid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update • Announces completion of enrollment in the pivotal Phase 3 NEPTUNE trial with OV101 in Angelman syndrome; topline resu
Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update NEW YORK, August 10, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologic
Read more →OVIDOvid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020
NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., MBA, President and Chief Me
Read more →OVIDOvid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome
Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing the underlying genetic cause of Angelman syndrome Ovid and UConn to collaborate
Read more →OVIDOvid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe
Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union and other countries in the European Economic Area, and also Switzerland, Turkey, the United Kingdo
Read more →OVIDOvid Therapeutics Added to Russell 2000 and Russell 3000 Indexes
NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Russell 2000® and the
Read more →OVIDOvid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome
Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome NEW YORK, June 19, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people w
Read more →OVIDJeremy Levin, DPhil, MB, BChir Chairman & Chief Executive Officer Ovid Therapeutics Welcome Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Priva
June 17, 2020 OV935 (soticlestat) Educational Seminar Exhibit 99.1 Jeremy Levin, DPhil, MB, BChir Chairman & Chief Executive Officer Ovid Therapeutics Welcome Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of
Read more →OVIDOvid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases
Broad multiyear alliance with Columbia University Irving Medical Center researchers to focus on development of potential medicines using genetic based therapies and create a therapeutic platform for a range of rare neurological conditions Ovid to collaborate with renowned clinic
Read more →OVIDOvid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights Platform
NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced multiple presentations across its rare neurological
Read more →OVIDOvid Therapeutics Launches Pipeline Teach-In Webinar Series
Company to host first webinar on Wednesday, June 17, to review OV935 (soticlestat) development program for rare developmental and epileptic encephalopathies (DEE) NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company commi
Read more →OVIDOvid Therapeutics Announces Participation in the 2020 RBC Capital Markets Virtual Global Healthcare Conference
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., MBA, President and Chief Med
Read more →OVIDOvid Therapeutics Announces Positive Topline Results from the Phase 2 ROCKET Trial of OV101 for the Treatment of Fragile X Syndrome
OV101 met the study’s primary objective of safety and tolerability OV101 produced statistically significant reductions in behavioral and functional symptoms in individuals with Fragile X syndrome Results support the continued development of OV101 in Fragile X syndrome NEW YORK
Read more →OVIDOvid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update • Announced earlier today positive topline results from the Phase 2 ROCKET trial of OV101 for the treatment of Fragile X
Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update NEW YORK, May 7, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological di
Read more →OVIDOvid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome Soticlestat continues to appear to be safe and well-tolerated; the majority of the 11 patients showed a reduction
Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome Soticlestat continues to appear to be safe and well-tolerated; the majority of the 11 patients showed a reduction in seizures All patients that have completed the Phase 2
Read more →OVIDOvid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020 • Multiple clinical data readouts across Ovid's pipeline expected in 2020 • Completed financ
Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020 NEW YORK, March 11, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people w
Read more →OVIDOvid Therapeutics Announces Multiple Presentations at the American Academy of Neurology 2020 Annual Meeting
NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced multiple poster presentations across its rare neur
Read more →OVIDOvid Therapeutics Names Alexander Kolevzon, M.D., to Scientific Advisory Board
NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Alexander Kolevzon, M.D., a lea
Read more →OVIDOvid Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
NEW YORK, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Jeremy Levin, DPhil, MB, BChir, Chairman and C
Read more →OVIDOvid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform OV101 (gaboxadol) in Neurodevelopmental Disorders: Topline Results From Pivotal Phase 3
Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform OV101 (gaboxadol) in Neurodevelopmental Disorders: OV935/TAK935 (soticlestat) in Rare Developmental and Epileptic Encephalopathies (DEE): NEW YOR
Read more →OVIDOvid Therapeutics to Participate at the 31st Annual Piper Jaffray Healthcare Conference
NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., President and Chief Medical
Read more →OVIDOvid Therapeutics Appoints Jason Tardio as Chief Commercial Officer
Seasoned CNS and Rare Disease Commercial Executive Further Strengthens Executive Management Team NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people wi
Read more →OVIDOvid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress Announced Positive Initial Results from the Ongoing ENDYMION trial with OV935 (Soticlestat) in Rare Epilepsies; Sustained and Progressive
Ovid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress Announced Positive Initial Results from the Ongoing ENDYMION trial with OV935 (Soticlestat) in Rare Epilepsies; Sustained and Progressively-Improving Median Seizure Frequency Reduction with Prolon
Read more →OVIDOvid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020 Amit Rakhit, M.D., MBA, Promoted to President Timothy Daly Promoted to Executive Vice President, Finance
Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020 Amit Rakhit, M.D., MBA, Promoted to President Timothy Daly Promoted to Executive Vice President, Finance NEW YORK, November 01, 2019 - Ovid Therapeutics Inc. (NA
Read more →OVIDOvid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock NEW YORK, Oct. 4, 2019 (GLOBE NEWSWIRE) Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines th
Read more →OVIDOvid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, today announced that it intends to offer and sell shares of its c
Read more →OVIDOvid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies
Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population Soticlestat Continues to Advance in Rare Epilepsies; Initial Data from Phase 2 ARCADE Trial Anticipated
Read more →OVIDDisclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan,"
Soticlestat (OV935) ENDYMION Update September 23, 2019 Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect,"
Read more →OVIDOvid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome OV101 May Become the First Medicine for Individuals with Angelman Syndrome; Topline Re
Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome OV101 May Become the First Medicine for Individuals with Angelman Syndrome; Topline Results Expected in Mid-2020 NEW YORK, September 12, 2019 -
Read more →OVIDOvid Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Jeremey Levin, DPhil, MB, BChir, Chairman and
Read more →OVIDOvid Therapeutics Announces Participation in Two Upcoming Investor Conferences
NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced its participation in two upcoming investor confere
Read more →OVIDOvid Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Recent Progress
Phase 3 NEPTUNE Trial of OV101 in Angelman Syndrome on Track to Enroll the First Patients in the Third Quarter of 2019 Regulatory Authorities in the U.S. and Germany agree that NEPTUNE, if positive, could support the filings of an NDA and MAA for OV101 Interim Data from Open-La
Read more →OVIDOvid Therapeutics (NASDAQ: OVID) is a New York-based biopharmaceutical company using its BoldMedicine approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad
Ovid Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Recent Progress Phase 3 NEPTUNE Trial of OV101 in Angelman Syndrome on Track to Enroll the First Patients in the Third Quarter of 2019 Regulatory Authorities in the U.S. and Germany agree that NEPTUN
Read more →OVIDOvid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome
Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome NEW YORK - July 2, 2019 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the live
Read more →OVIDOvid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome; Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020 Phase 3 NEPTUNE Trial of OV101 Expected
Ovid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome; Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020 Phase 3 NEPTUNE Trial of OV101 Expected to Enroll the First Patients in the Third Quarter of 2019;
Read more →OVIDOvid Therapeutics to Host R&D Day on
Ovid Therapeutics to Host R&D Day on June 27, 2019 Program to feature regulatory and clinical program updates and presentations from thought leaders on Angelman syndrome, Fragile X syndrome, and rare developmental and epileptic encephalopathies (DEE) NEW YORK - June 18, 2019 -
Read more →OVIDOvid Therapeutics to Host R&D Day on June 27, 2019
NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced that it will host an R&D Day on Thursday, June 27,
Read more →OVIDCertain confidential information contained in this document, marked by brackets, is omitted because it is not material and would be competitively harmful if publicly disclosed. IN WITNESS WHEREOF , this Amendment is here
[***] = Certain confidential information contained in this document, marked by brackets, is omitted because it is not material and would be competitively harmful if publicly disclosed. THIS FIRST AMENDMENT TO LICENSE AGREEMENT (this "Amendment") is made as of this 10th day of Ma
Read more →OVIDOvid Therapeutics Reports First Quarter 2019 Financial Results Remains on track for all previously stated milestones expected throughout 2019 The STARS study selected as one of three abstracts featured at the 2019 AAN To
Ovid Therapeutics Reports First Quarter 2019 Financial Results Remains on track for all previously stated milestones expected throughout 2019 The STARS study selected as one of three abstracts featured at the 2019 AAN Top Science Press Conference NEW YORK - May 07, 2019 - Ovid
Read more →OVIDOvid Therapeutics to Present at the American Academy of Neurology 71st Annual Meeting
Emerging Science platform presentation highlights efficacy and safety data of OV101 in Angelman syndrome from the STARS study Research from Ovid’s Fragile X program shows new insights for outcome assessments NEW YORK, April 18, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (N
Read more →OVIDInvestors: Investor Relations & Public Relations Ovid Therapeutics Inc. irpr@ovidrx.com Alex Gray Burns McClellan, Inc. agray@burnsmc.com (212) 213-0006 Media: Jerica Pitts W2Opure jpitts@purecommunications.com
Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline NEW YORK - March 28, 2019 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people wit
Read more →OVIDOvid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline
Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline NEW YORK - March 28, 2019 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people wit
Read more →OVIDOvid Therapeutics Announces Appointment of Pharmaceutical Veteran, Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary
Ovid Therapeutics Announces Appointment of Pharmaceutical Veteran, Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary NEW YORK - March 21, 2019 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines th
Read more →OVIDOvid Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Ovid Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results NEW YORK - March 7, 2019 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, toda
Read more →OVIDOvid Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference on Monday, March 11
NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Jeremy Levin, DPhil, MB BChir, Chairman and C
Read more →OVIDOvid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common NEW YORK, February 20, 2019 (GLOBE NEWSWIRE) Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives o
Read more →OVIDForward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and
Ovid Therapeutics Corporate Presentation February 2019 Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anti
Read more →OVIDOvid Therapeutics Outlines 2019 Clinical and Business Priorities -- OV101 in Angelman syndrome : Pivotal Phase 3 NEPTUNE trial expected to begin in second half 2019 -- -- OV101 in Fragile X syndrome : Phase 2 ROCKET clin
Ovid Therapeutics Outlines 2019 Clinical and Business Priorities -- OV101 in Angelman syndrome: Pivotal Phase 3 NEPTUNE trial expected to begin in second half 2019 -- -- OV101 in Fragile X syndrome: Phase 2 ROCKET clinical trial results in adolescents and young adults expected
Read more →OVIDcollaboration with Takeda Pharmaceutical Company Limited for the treatment of rare developmental and epileptic encephalopathies (DEE). For more information on Ovid, please visit http://www.ovidrx.com/ . Forward-Looking S
Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies -- Met primary endpoint of safety and tolerability -- -- A dose-dependent reduction of plasma 24HC levels was observed, consistent with target engagement -- -- Exploratory analysis
Read more →OVIDOvid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies
-- Met primary endpoint of safety and tolerability -- -- A dose-dependent reduction of plasma 24HC levels was observed, consistent with target engagement -- -- Exploratory analysis of clinical activity of OV935 shows a decrease in seizure frequency associated with the drop in 2
Read more →OVIDOvid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome -- Single pivotal Phase 3 trial design, using once-daily dosing, may be
Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome -- Single pivotal Phase 3 trial design, using once-daily dosing, may be sufficient for approval of OV101 in Angelman syndrome-- --
Read more →OVIDOvid Therapeutics Announces OV935/TAK-935 Presentations at the American Epilepsy Society 72nd Annual Meeting
NEW YORK, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it will present two poster presentations and o
Read more →OVIDOvid Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27
NEW YORK, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will present at the 30th Annual Pi
Read more →OVIDOvid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress -- OV101 in Angelman syndrome: Plan to meet with U.S. FDA in the fourth quarter of 2018 to review Phase 2 STARS resul
Ovid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress -- OV101 in Angelman syndrome: Plan to meet with U.S. FDA in the fourth quarter of 2018 to review Phase 2 STARS results and discuss next steps for program -- -- OV935/TAK-935
Read more →OVIDOvid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 for the Treatment of Angelman Syndrome at the 65th AACAP Annual Meeting
-- Additional data and analyses suggest that in the OV101 15 mg once-daily dose group, changes in sleep parameters and motor domains contributed to the statistically significant improvement in overall clinical global symptoms (CGI-I) observed in previously announced topline data
Read more →OVIDAbout Angelman Syndrome Angelman syndrome is a genetic disorder that is characterized by a variety of signs and symptoms. Characteristic features of this disorder include delayed development, intellectual disability, sev
Embargoed Until 10/25/2018 9am EDT Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 for the Treatment of Angelman Syndrome at the 65th AACAP Annual Meeting -- Additional data and analyses suggest that in the OV101 15 mg on
Read more →OVIDOvid Therapeutics Receives “Company Making a Difference Award” from CDKL5 Deficiency Disorder Community
NEW YORK, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced it has received the 2018 CDKL5 Forum Company Making
Read more →OVIDOvid Therapeutics to Host Conference Call and Webcast on Thursday, October 25, at 10:30 a.m. EDT
-- Alexander Kolevzon, M.D., to review additional data from company’s Phase 2 STARS trial with OV101 for the treatment of Angelman syndrome during the 65th American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting -- NEW YORK, Oct. 22, 2018 (GLOBE NEWSWIRE) -- O
Read more →OVIDovid-ex991_91.pptx.htm Corporate Presentation Cantor Fitzgerald Global Healthcare Conference
Corporate Presentation Cantor Fitzgerald Global Healthcare Conference October 1, 2018 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect
Read more →OVIDOvid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies
-- OV935 is being investigated for the treatment of pediatric patients with Dravet or Lennox-Gastaut syndromes in the ELEKTRA trial and pediatric patients with CDKL5 deficiency or Dup15q syndromes in the ARCADE trial -- NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeut
Read more →OVIDOvid Therapeutics to Present at Two Investor Healthcare Conferences in October 2018
NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will present at two upcoming inve
Read more →OVIDOvid Therapeutics to Present at Two Investor Healthcare Conferences in September 2018
NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will present at two upcoming invest
Read more →OVIDOvid Therapeutics Announces Phase 2 STARS Topline Data Accepted for Presentation at American Academy of Child And Adolescent Psychiatry Annual Meeting
- Poster presentation of STARS topline data: the first clinical trial to show a positive clinical benefit on overall Angelman syndrome impairments - NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to deve
Read more →OVIDOvid Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Recent Clinical Progress -- OV101 in Angelman syndrome: plan to initiate an open-label extension study (ELARA) in the fourth quarter of 2018
Ovid Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Recent Clinical Progress -- OV101 in Angelman syndrome: plan to initiate an open-label extension study (ELARA) in the fourth quarter of 2018 and discuss with regulatory authorities next steps for a re
Read more →OVIDOvid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome
-- OV101 achieved primary endpoint of safety and tolerability -- -- Robust and statistically significant improvement (p=0.0006) in the first prespecified efficacy endpoint (CGI-I) observed at 12 weeks of treatment in once-daily dose group compared to placebo -- -- STARS data su
Read more →OVIDAbout OV101 OV101 (gaboxadol) is believed to be the only delta ( )-selective GABA A receptor agonist in development and the first investigational drug to specifically target the disruption of tonic inhibition, a central
Ovid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome -- OV101 achieved primary endpoint of safety and tolerability -- -- Robust and statistically significant improvement (p=0.0006) in the first prespecified e
Read more →OVIDAgenda SPEAKERS AGENDA ITEM Lora Pike Senior Director, IR & PR Welcome Jeremy Levin, DPhil, MB BChir Chairman & CEO Initial Remarks and OV101 Program Strategy Amit Rakhit, MD, MBA Chief Medical & Portfolio Management Off
Phase 2 STARS Trial Achieves Primary Endpoint and Shows Statistically Significant Improvements in CGI-I August 6, 2018 Exhibit 99.1 Agenda SPEAKERS AGENDA ITEM Lora Pike Senior Director, IR & PR Welcome Jeremy Levin, DPhil, MB BChir Chairman & CEO Initial Remarks and OV101 Progr
Read more →OVIDTakeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with Three New Studies in Rare Developmental and Epileptic Encephalopathies (DEE) Broad clinical program to include three studies expected to begin i
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with Three New Studies in Rare Developmental and Epileptic Encephalopathies (DEE) Broad clinical program to include three studies expected to begin in the third quarter of calendar year 2018 in addition to th
Read more →OVIDOvid Therapeutics Announces Presentations Related to OV101 Fragile X Syndrome Program at the 16th National Fragile X Foundation (NFXF) International Conference
CINCINNATI, July 11, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced several presentations related to the OV101 Fragile
Read more →OVIDOvid Therapeutics Announces Initiation of Phase 2 ROCKET Clinical Trial to Evaluate OV101 in Fragile X Syndrome Phase 2 trial will evaluate OV101 for 12 weeks in up to 30 males aged 13 to 22
Ovid Therapeutics Announces Initiation of Phase 2 ROCKET Clinical Trial to Evaluate OV101 in Fragile X Syndrome Phase 2 trial will evaluate OV101 for 12 weeks in up to 30 males aged 13 to 22 NEW YORK -July 11, 2018 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical co
Read more →OVIDOvid Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference on June 8, 2018
NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present a corporate overview at
Read more →OVIDOvid Therapeutics Announces Two Oral Presentations at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV)
New preclinical data provide further evidence of TAK-935/OV935’s novel mechanism of action, as a potential treatment for rare developmental and epileptic encephaolopathies (dEE) First presentation of preclinical data on OV329, a potential new therapeutic approach for treatment-r
Read more →OVIDOvid Therapeutics Reports First Quarter 2018 Financial Results and Corporate Progress - Data readouts for Ovid s two lead programs expected in 2018: OV101 STARS trial for adults and adolescents with Angelman syndrome (AS
Ovid Therapeutics Reports First Quarter 2018 Financial Results and NEW YORK May 8, 2018 Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today reported finan
Read more →OVIDOvid Therapeutics to Present at Deutsche Bank’s 43rd Annual Health Care Conference on May 9, 2018
NEW YORK, May 02, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced that management will present a corporate overview at
Read more →OVIDOvid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Progress Enrollment Completed in Phase 2 STARS Clinical Trial in Adults and Adolescents with Angelman Syndrome; Topline Data Exp
Ovid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Progress Enrollment Completed in Phase 2 STARS Clinical Trial in Adults and Adolescents with Angelman Syndrome; Topline Data Expected Third Enrollment Ongoing in Phase 1b/2a Clinical Tr
Read more →OVIDOvid Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Thursday, March 29, 2018
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that its fourth quarter and full year 2017 financial results will be rel
Read more →OVIDOvid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Fragile X Syndrome
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) ha
Read more →OVIDOvid Therapeutics to Present at Two Upcoming Investor Conferences
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that members of the company’s management team will present at two upcomi
Read more →OVIDOvid Therapeutics Announces Multiple Poster Presentations of OV101 and TAK-935/OV935 at the American Academy of Neurology 70th Annual Meeting
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it will present five poster presentations on O
Read more →OVIDOvid Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that Yaron Werber, MD, chief business and financial officer of Ovid, will
Read more →OVIDOvid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation by U.S. FDA for Treatment of Lennox-Gastaut Syndrome
NEW YORK, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the United States Food and Drug Administration
Read more →OVIDOvid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome
NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has
Read more →OVIDOvid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome
Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome NEW YORK December 5, 2017 Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives
Read more →OVIDOvid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting
- Phase 1 Clinical Trials of TAK-935/OV935 Demonstrated a Strong Safety Profile and Well Characterized Pharmacokinetic Profile, Supporting Further Clinical Advancement - - Results Support Plasma 24S-hydroxycholesterol (24HC) as a Potential Biomarker of TAK-935/OV935 Treatment -
Read more →OVIDOvid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase 1 Study of Adolescent Patients and Amends Phase 2 STARS Clinical Trial Protocol to Include Adolescents Results from the Phase 1 Clinical Trial of Ado
Ovid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase 1 Study of Adolescent Patients and Amends Phase 2 STARS Clinical Trial Protocol to Include Adolescents Results from the Phase 1 Clinical Trial of Adolescents with Angelman and Fragile X Syndromes Demonstra
Read more →OVIDOvid Therapeutics Announces Five Poster Presentations on TAK-935/OV935 at the American Epilepsy Society 71st Annual Meeting
NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced that it will present five poster presentations on TAK-935/OV935 at the Ame
Read more →OVIDOvid Therapeutics to Participate in Two Upcoming Investor Conferences
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that it will participate in two upcoming investor conferences: 29th Annu
Read more →OVIDOvid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress
Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress NEW YORK November 9, 2017 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced f
Read more →OVIDOvid Therapeutics to Participate at the Stifel 2017 Healthcare Conference
NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that Jeremy Levin, DPhil, MB BChir, chairman and chief executive officer,
Read more →OVIDOvid Therapeutics Announces Positive Preclinical OV101 Data Demonstrating Behavioral Improvements in Fragile X Syndrome Model
Ovid Therapeutics Announces Positive Preclinical OV101 Data Demonstrating Behavioral Improvements in Fragile X Syndrome Model NEW YORK October 16, 2017 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines for patients with rare
Read more →OVIDOvid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for Treatment of Fragile X Syndrome
Ovid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for Treatment of Fragile X NEW YORK October 10, 2017 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rar
Read more →OVIDOvid Therapeutics to Present Preclinical Data Demonstrating OV101 Normalizes Behavioral Abnormalities at the 18th International Fragile X and Related Neurodevelopmental Disorders Workshop
NEW YORK, Oct. 05, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced that it will provide a poster presentation of preclinical data on OV101, a
Read more →OVIDOvid Therapeutics Appoints Ana C. Ward as Senior Vice President and General Counsel
NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced the appointment of Ana C. Ward as senior vice president and general coun
Read more →OVIDOvid Therapeutics Announces First Patient Randomized in Phase 1b/2a Clinical Trial of TAK-935/OV935 in Adults with Rare Epilepsies
- Cornerstone of Robust Clinical Development Strategy for Potential First-in-Class CH24H Modulator - - Ovid’s Clinical Pipeline of Rare Neurological Disorder Programs Advancing to Mid-Stage Trials - NEW YORK, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OV
Read more →OVIDForward-Looking Statements This presentation contains projections for Ovid Therapeutics Inc. ("Ovid") and other forward-looking information. Such projections and information are based on assumptions as to future events t
Corporate Presentation August 15, 2017 Forward-Looking Statements This presentation contains projections for Ovid Therapeutics Inc. ("Ovid") and other forward-looking information. Such projections and information are based on assumptions as to future events that are inherently
Read more →OVIDOvid Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Progress
Ovid Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Progress NEW YORK August 10, 2017 Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced fin
Read more →OVIDOvid Therapeutics to be Added to Russell 2000 , 3000 and Microcap Indexes
NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that it will be added to the Russell 2000®, 3000® and Microcap® Indexes,
Read more →OVIDOvid Therapeutics Appoints Barbara G. Duncan to its Board of Directors Ms. Duncan to serve as chairperson of Audit Committee
Ovid Therapeutics Appoints Barbara G. Duncan to its Board of Directors Ms. Duncan to serve as chairperson of Audit Committee NEW YORK June 14, 2017 Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurol
Read more →OVIDOvid Therapeutics Reports First Quarter 2017 Financial Results and Recent Corporate Progress Completed Initial Public Offering Raising $75 Million in Gross Proceeds Initiated Phase 2 STARS Clinical Trial of OV101 in Adul
Ovid Therapeutics Reports First Quarter 2017 Financial Results and Recent Completed Initial Public Offering Raising $75 Million in Gross Proceeds Initiated Phase 2 STARS Clinical Trial of OV101 in Adults with Angelman Syndrome Entered into Innovative Global Collaboration with
Read more →OVIDOvid Therapeutics to Participate in the JMP Securities 2017 Life Sciences Conference
NEW YORK, June 12, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that Yaron Werber, MD, chief business and financial officer of Ovid, will
Read more →OVIDOvid Therapeutics to Present Preclinical Data on TAK-935/OV935 at the Antiepileptic Drug and Device Trials XIV Conference
NEW YORK, May 12, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc., (NASDAQ:OVID) a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced that it will present preclinical data on TAK-935/OV935, a potent and highly
Read more →OVIDOvid Therapeutics Inc. (Nasdaq: OVID) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, May 09, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, will visit the Nasdaq MarketSite in Times Square. In honor of the o
Read more →OVIDOvid Therapeutics Announces Pricing of Initial Public Offering
NEW YORK, May 04, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc., a biopharmaceutical company, announced today that it has priced its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share, for an aggregate offering of $75
Read more →OVIDOvid Therapeutics Announces Initiation of Phase 1 Clinical Trial of OV101 for Adolescents with Angelman Syndrome or Fragile X Syndrome
NEW YORK, April 10, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics, Inc., a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has initiated a Phase 1 clinical trial to
Read more →OVIDOvid Therapeutics and NeuroPointDX Announce Collaboration to Identify Biomarkers for Angelman Syndrome
NEW YORK and MADISON, Wis., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics, a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, and NeuroPointDX, a privately held biotech company ba
Read more →OVIDOvid Therapeutics Announces First Patient Randomized in the Phase 2 STARS Clinical Trial in Adults with Angelman Syndrome
NEW YORK, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics, a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced it has randomized the first patient in its STARS trial
Read more →OVIDOvid Therapeutics Names Jacqueline A. French, M.D. to Scientific Advisory Board
NEW YORK, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics, a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Jacqueline A. French, M.D., a world-r
Read more →Competitive Position
How OVID ranks across every disease it competes inCompetitive Position is a premium feature
See how OVID ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial